Contract Pharma Manufacturing News

  1. Upperton Pharma Solutions Awarded VaxHub Sustainable Grant To Advance Oral Vaccine Delivery In Partnership With The University Of Oxford's Pandemic Sciences Institute 8/18/2025

    Upperton Pharma Solutions, a leading UK-based CDMO, has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford. The funding supports the development of an oral formulation for Adenovirus-vectored vaccines.

  2. WuXi Biologics Ireland Facility Receives First EMA Approval For Commercial Manufacturing Of Innovative Biologic 8/18/2025

    WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Dundalk, Ireland facility has received its first approval from European Medicines Agency (EMA) as a commercial manufacturing site for a global client’s innovative biologic.

  3. Vcare Enters Into Exclusive Partnership With Huadong Medicine To Commercialize Its Second-Generation JAK1 Inhibitor, VC005 Tablets, In China 8/15/2025

    Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare's innovative product VC005 tablets in mainland China.

  4. ScaleReady Announces Award Of A G-Rex® Grant To The Gates Institute's Translational Sciences Laboratory 8/14/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform.

  5. Made Scientific And New Jersey Delegates Celebrate Grand Opening Of Flagship Cell Therapy Manufacturing Facility 8/14/2025

    Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), held a ribbon-cutting ceremony yesterday to commemorate the grand opening of its new 60,000 sq. ft. GMP manufacturing facility and headquarters in Princeton, New Jersey.

  6. Superluminal Medicines Announces Collaboration With Eli Lilly And Company To Advance Small Molecule Therapeutics For Cardiometabolic Diseases And Obesity 8/14/2025

    Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company ("Lilly") to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity.

  7. BioDlink Accelerates Global Expansion With Bevacizumab Launch In Colombia And Pakistan 8/13/2025

    BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia's National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan's Drug Regulatory Authority of Pakistan (DRAP).

  8. Pace® Life Sciences Debuts Enhanced cGMP Manufacturing Capabilities To Support Increasing Demand For Sterile Injectables 8/12/2025

    Pace® Life Sciences, a U.S.-based CRDMO and full-service FDA-registered GMP Analytical Testing laboratory re-opened its 33,000 square foot facility in Salem, NH with advanced technologies to support small batch manufacturing.

  9. Lupin Announces Licensing Deal For Ranibizumab Biosimilar 8/12/2025

    Global Pharma major Lupin Limited (Lupin) today announced that it has partnered with Sandoz Group AG (Sandoz), Switzerland, to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions.

  10. Primo Biotech And Anbogen Therapeutics Forge Co-Develop Precision Radioligand For Solid Tumors Diagnosis And Therapy 8/12/2025

    Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a prominent biotech firm specializing in novel drug development.